Logo image of CLYM

CLIMB BIO INC (CLYM) Stock Fundamental Analysis

NASDAQ:CLYM - Nasdaq - US28658R1068 - Common Stock - Currency: USD

1.23  -0.03 (-2.38%)

After market: 1.23 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CLYM. CLYM was compared to 568 industry peers in the Biotechnology industry. CLYM has a great financial health rating, but its profitability evaluates not so good. CLYM does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CLYM has reported negative net income.
In the past year CLYM has reported a negative cash flow from operations.
CLYM had negative earnings in each of the past 5 years.
CLYM had a negative operating cash flow in each of the past 5 years.
CLYM Yearly Net Income VS EBIT VS OCF VS FCFCLYM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of CLYM (-34.02%) is better than 62.32% of its industry peers.
With a decent Return On Equity value of -34.88%, CLYM is doing good in the industry, outperforming 73.77% of the companies in the same industry.
Industry RankSector Rank
ROA -34.02%
ROE -34.88%
ROIC N/A
ROA(3y)-33.11%
ROA(5y)-44.53%
ROE(3y)-34.22%
ROE(5y)-48.01%
ROIC(3y)N/A
ROIC(5y)N/A
CLYM Yearly ROA, ROE, ROICCLYM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

CLYM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLYM Yearly Profit, Operating, Gross MarginsCLYM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, CLYM has more shares outstanding
CLYM has more shares outstanding than it did 5 years ago.
CLYM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLYM Yearly Shares OutstandingCLYM Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLYM Yearly Total Debt VS Total AssetsCLYM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 8.32 indicates that CLYM is not in any danger for bankruptcy at the moment.
CLYM has a better Altman-Z score (8.32) than 87.68% of its industry peers.
There is no outstanding debt for CLYM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.32
ROIC/WACCN/A
WACCN/A
CLYM Yearly LT Debt VS Equity VS FCFCLYM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

CLYM has a Current Ratio of 31.41. This indicates that CLYM is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CLYM (31.41) is better than 98.59% of its industry peers.
A Quick Ratio of 31.41 indicates that CLYM has no problem at all paying its short term obligations.
CLYM has a better Quick ratio (31.41) than 98.59% of its industry peers.
Industry RankSector Rank
Current Ratio 31.41
Quick Ratio 31.41
CLYM Yearly Current Assets VS Current LiabilitesCLYM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for CLYM have decreased strongly by -62.56% in the last year.
EPS 1Y (TTM)-62.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.52%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CLYM is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.15% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y22.91%
EPS Next 2Y3.39%
EPS Next 3Y17.74%
EPS Next 5Y6.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CLYM Yearly EPS VS EstimatesCLYM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CLYM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CLYM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLYM Price Earnings VS Forward Price EarningsCLYM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLYM Per share dataCLYM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

CLYM's earnings are expected to grow with 17.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.39%
EPS Next 3Y17.74%

More info and screens

0

5. Dividend

5.1 Amount

CLYM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLIMB BIO INC

NASDAQ:CLYM (4/21/2025, 8:03:12 PM)

After market: 1.23 0 (0%)

1.23

-0.03 (-2.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25 2025-03-25/amc
Earnings (Next)N/A N/A
Inst Owners86.56%
Inst Owner ChangeN/A
Ins Owners0.75%
Ins Owner Change42.63%
Market Cap83.00M
Analysts85.71
Price Target10.2 (729.27%)
Short Float %3.31%
Short Ratio4.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)6.06%
EPS NY rev (3m)4.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB 0.39
EV/EBITDA N/A
EPS(TTM)-1.72
EYN/A
EPS(NY)-1.6
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0
BVpS3.14
TBVpS3.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.02%
ROE -34.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.11%
ROA(5y)-44.53%
ROE(3y)-34.22%
ROE(5y)-48.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 31.41
Quick Ratio 31.41
Altman-Z 8.32
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.52%
EPS Next Y22.91%
EPS Next 2Y3.39%
EPS Next 3Y17.74%
EPS Next 5Y6.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.45%
OCF growth 3YN/A
OCF growth 5YN/A